Zhang J, Wang Q, Yuan W, Li J, Yuan Q, Zhang J
J Virol. 2024; 98(8):e0192923.
PMID: 39078152
PMC: 11334434.
DOI: 10.1128/jvi.01929-23.
Lazarevic I, Banko A, Miljanovic D, Cupic M
Pathogens. 2024; 13(1).
PMID: 38251353
PMC: 10818932.
DOI: 10.3390/pathogens13010046.
Parizad E, Fooladi A, Sedighian H, Behzadi E, Amani J, Khosravi A
Virus Genes. 2023; 59(4):499-514.
PMID: 37140777
DOI: 10.1007/s11262-023-01995-z.
Vesikari T, Finn A, Van Damme P, Leroux-Roels I, Leroux-Roels G, Segall N
JAMA Netw Open. 2021; 4(10):e2128652.
PMID: 34636914
PMC: 8511978.
DOI: 10.1001/jamanetworkopen.2021.28652.
Whitacre D, Peters C, Sureau C, Nio K, Li F, Su L
Hum Vaccin Immunother. 2019; 16(2):251-268.
PMID: 31809638
PMC: 7062423.
DOI: 10.1080/21645515.2019.1689745.
A Global View to HBV Chronic Infection: Evolving Strategies for Diagnosis, Treatment and Prevention in Immunocompetent Individuals.
Nicolini L, Orsi A, Tatarelli P, Viscoli C, Icardi G, Sticchi L
Int J Environ Res Public Health. 2019; 16(18).
PMID: 31505743
PMC: 6766235.
DOI: 10.3390/ijerph16183307.
Biotechnology and the transformation of vaccine innovation: The case of the hepatitis B vaccines 1968-2000.
Huzair F, Sturdy S
Stud Hist Philos Biol Biomed Sci. 2017; 64:11-21.
PMID: 28511068
PMC: 5541201.
DOI: 10.1016/j.shpsc.2017.05.004.
A randomized, controlled clinical trial to evaluate the immunogenicity of a PreS/S hepatitis B vaccine Sci-B-Vac™, as compared to Engerix B, among vaccine naïve and vaccine non-responder dialysis patients.
Elhanan E, Boaz M, Schwartz I, Schwartz D, Chernin G, Soetendorp H
Clin Exp Nephrol. 2017; 22(1):151-158.
PMID: 28456864
DOI: 10.1007/s10157-017-1416-7.
Associations between pre-S deletion mutation of hepatitis B virus and risk of hepatocellular carcinoma in the Asian population: a meta-analysis.
Wang C, Teng Z, Zhu Y, Zhao A, Sun C
Med Sci Monit. 2015; 21:1072-7.
PMID: 25868851
PMC: 4410724.
DOI: 10.12659/MSM.894058.
Generation of hepatitis B virus PreS2-S antigen in Hansenula polymorpha.
Xu X, Ren S, Chen X, Ge J, Xu Z, Huang H
Virol Sin. 2014; 29(6):403-9.
PMID: 25547684
PMC: 8206452.
DOI: 10.1007/s12250-014-3508-9.
Prophylactic vaccination against hepatitis B: achievements, challenges and perspectives.
Gerlich W
Med Microbiol Immunol. 2014; 204(1):39-55.
PMID: 25523195
DOI: 10.1007/s00430-014-0373-y.
Immunogenicity and safety of Advax™, a novel polysaccharide adjuvant based on delta inulin, when formulated with hepatitis B surface antigen: a randomized controlled Phase 1 study.
Gordon D, Kelley P, Heinzel S, Cooper P, Petrovsky N
Vaccine. 2014; 32(48):6469-77.
PMID: 25267153
PMC: 4253909.
DOI: 10.1016/j.vaccine.2014.09.034.
A novel hepatitis B vaccine containing Advax™, a polysaccharide adjuvant derived from delta inulin, induces robust humoral and cellular immunity with minimal reactogenicity in preclinical testing.
Saade F, Honda-Okubo Y, Trec S, Petrovsky N
Vaccine. 2013; 31(15):1999-2007.
PMID: 23306367
PMC: 3606636.
DOI: 10.1016/j.vaccine.2012.12.077.
Pre-s mutation is a significant risk factor for hepatocellular carcinoma development: a long-term retrospective cohort study.
Sinn D, Choi M, Gwak G, Paik Y, Lee J, Koh K
Dig Dis Sci. 2012; 58(3):751-8.
PMID: 23053886
DOI: 10.1007/s10620-012-2408-9.
Use of pre-S protein-containing hepatitis B virus surface antigens and a powerful adjuvant to develop an immune therapy for chronic hepatitis B virus infection.
Yum J, Ahn B, Jo H, Kim D, Kim K, Kim H
Clin Vaccine Immunol. 2011; 19(2):120-7.
PMID: 22155769
PMC: 3272936.
DOI: 10.1128/CVI.05355-11.
Design of therapeutic vaccines: hepatitis B as an example.
Kutscher S, Bauer T, Dembek C, Sprinzl M, Protzer U
Microb Biotechnol. 2011; 5(2):270-82.
PMID: 21958338
PMC: 3815787.
DOI: 10.1111/j.1751-7915.2011.00303.x.
Virological pattern of hepatitis B infection in an HIV-positive man with fatal fulminant hepatitis B: a case report.
Bagaglio S, Albarello L, Biswas P, Uberti-Foppa C, Fortis C, Morsica G
J Med Case Rep. 2009; 3:110.
PMID: 19946588
PMC: 2783051.
DOI: 10.1186/1752-1947-3-110.
Expression of the human hepatitis B virus large surface antigen gene in transgenic tomato plants.
Lou X, Yao Q, Zhang Z, Peng R, Xiong A, Wang H
Clin Vaccine Immunol. 2007; 14(4):464-9.
PMID: 17314228
PMC: 1865599.
DOI: 10.1128/CVI.00321-06.
Virus-like particles production in green plants.
Santi L, Huang Z, Mason H
Methods. 2006; 40(1):66-76.
PMID: 16997715
PMC: 2677071.
DOI: 10.1016/j.ymeth.2006.05.020.
Immunological response to two hepatitis B vaccines administered in two different schedules.
Girisha K, Kamat J, Nataraj G
Indian J Pediatr. 2006; 73(6):489-91.
PMID: 16816509
DOI: 10.1007/BF02759892.